|
|
Article: FDA Grants Marketing Clearance of Gilead's VISTIDE for the Treatment of CMV Retinitis in Patients with AIDS; Vistide Marks Gilead's First Commercial Product.
- Article from:
- Business Wire
- Article date:
- June 27, 1996
CopyrightCOPYRIGHT 1996 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FOSTER CITY, Calif.--(HealthWire)--June 27, 1996--Gilead Sciences Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) granted marketing clearance of VISTIDE(R) (cidofovir injection) for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. CMV retinitis is a sight-threatening viral infection that progresses rapidly and may lead to blindness.
Gilead shipped VISTIDE within hours of approval to wholesaler and specialty distributors nationwide. The Company will independently market VISTIDE in the United States with an antiviral specialty sales force.
"Patients with AIDS are terrified of the possibility of going ...